Category: Non classé

PEACCEL co-authored a critical review on VHH structural modelling approaches with its academic partners

Posted on by adminds

VHH, i.e., VH domains of camelid single-chain antibodies, are very promising therapeutic agents due to their significant physicochemical advantages compared to classical mammalian antibodies. Unfortunately, most VHHs do not have 3D structures. This review presents the most extensive overview of structure prediction methods applied for the 3D modelling of a given VHH sequence (a total of 21). AlphaFold 2 and NanoNet appear to be the best tools to predict a structural model of VHH from its sequence.

Read more…

PEACCEL and SYNTHELIS have signed a strategic partnership to increase the chances of success of your drugs

Posted on by adminds

PEACCEL and SYNTHELIS have signed a strategic partnership to offer their clients and partners a one-stop shop combining Artificial Intelligence (AI) and Cell-Free lead expression for accelerated drug discovery.

Read more..

PEACCEL and SYNTHELIS have signed a strategic partnership to offer their clients and partners a one-stop shop combining Artificial Intelligence (AI) and Cell-Free lead expression for accelerated drug discovery.

Read more..

PEACCEL listed in the Global AI-based Drug Discovery Market Report 2021: Market report by Cision (NYSE: CISN).

Posted on by adminds

PEACCEL listed in the Global AI-based Drug Discovery Market Report 2021:  Market report by Cision (NYSE: CISN).

https://www.prnewswire.com/news-releases/global-ai-based-drug-discovery-market-report-2021-current-market-landscape-and-future-potential-of-the-players-engaged-in-offering-ai-based-services-platforms-and-tools—forecast-to-2030-301231782.html